Eli Lilly and Company-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2023

  1. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

    Alzheimer's and Dementia, Vol. 19, Núm. 5, pp. 1800-1820

  2. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

    Rheumatology and Therapy, Vol. 10, Núm. 5, pp. 1319-1333

2022

  1. Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study) (Rheumatology and Therapy, (2022), 9, 2, (589-608), 10.1007/s40744-021-00423-8)

    Rheumatology and Therapy

  2. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

  3. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

  4. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)

    Rheumatology and Therapy, Vol. 9, Núm. 2, pp. 589-608

2021

  1. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

    The Lancet Respiratory Medicine, Vol. 9, Núm. 12, pp. 1407-1418

  2. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 20-30

2019

  1. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

  2. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

    Parkinsonism and Related Disorders, Vol. 60, pp. 138-145

2018

  1. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

    Annals of Clinical and Translational Neurology, Vol. 5, Núm. 12, pp. 1460-1477

2012

  1. Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: A microdialysis study

    Journal of Neuroscience Research, Vol. 90, Núm. 3, pp. 588-596

2011

  1. 2-year course of bipolar disorder type I patients in outpatient care: Factors associated with remission and functional recovery

    European Neuropsychopharmacology, Vol. 21, Núm. 4, pp. 287-293

  2. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania - Results of a two year observational study in bipolar disorder (EMBLEM)

    Journal of Affective Disorders, Vol. 131, Núm. 1-3, pp. 320-329

  3. Gender differences in outcomes of acute mania: A 12-month follow-up study

    Archives of Women's Mental Health, Vol. 14, Núm. 2, pp. 107-113

2010

  1. Assessment of medication adherence in a cohort of patients with bipolar disorder

    Pharmacopsychiatry, Vol. 43, Núm. 7, pp. 263-270

  2. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania

    Journal of Clinical Psychiatry, Vol. 71, Núm. 3, pp. 255-261

  3. Comparison of olanzapine and risperidone in the EMBLEM Study: Translation of randomized controlled trial findings into clinical practice

    International Clinical Psychopharmacology, Vol. 25, Núm. 5, pp. 257-263

2009

  1. Observational study designs for bipolar disorder - What can they tell us about treatment in acute mania?

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 33, Núm. 4, pp. 715-721

  2. Translation of randomised controlled trial findings into clinical practice: Comparison of olanzapine and valproate in the EMBLEM study

    Pharmacopsychiatry, Vol. 42, Núm. 4, pp. 145-152